In a cost-minimization analysis in type 2 diabetes with established cardiovascular disease, the cost to prevent one cardiovascular death was higher with liraglutide than with empagliflozin.
In plain wordsIn a cost analysis for type 2 diabetes with heart disease, preventing one heart death cost more with liraglutide than with empagliflozin.
- Peptide
- Liraglutide
- Outcome
- Not applicableDrug cost needed to prevent one cardiovascular death
- Study
humann: not reported in source
- Comparator
- Empagliflozin
- Outcome group
- Cardiovascular events · Cardiovascular
Source sentences
Therefore, the cost of Empagliflozin or Liraglutide needed to prevent 1 CV death would be $569,526 (95% confidence interval $415,713 to $921,798) and $2,575,312 (95% confidence interval $1,607,526 to $7,807,986), respectively.
1 context sentence(design, population, supporting numbers)
We performed a cost-minimization analysis of Empagliflozin versus Liraglutide for preventing CV death.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.